Show simple item record

dc.contributor.authorJurua, Maria
dc.date.accessioned2019-09-23T13:13:54Z
dc.date.available2019-09-23T13:13:54Z
dc.date.created2017-12-15 00:19
dc.date.issued2017-12-05
dc.identifieroai:ojs.ajol.info:article/163623
dc.identifierhttps://www.ajol.info/index.php/ad/article/view/163623
dc.identifier.urihttp://hdl.handle.net/20.500.12424/24430
dc.description.abstractIs access to medicines at risk despite the Doha Declaration? What are the alternative mechanisms that should be instituted to guarantee continued access to life saving drugs for many in the least developed countries (LDCs)? The Doha Declaration affirmed that patent rules should be interpreted and implemented to protect public health. Since Doha, access to drugs has dramatically increased to reach more than five billion people in developing countries. The Doha declaration also gave WTO members that are among the least-developed countries, an extended transition period, until 1 January 2016, with regard to pharmaceutical patents and test data protection for pharmaceutical products. The transition period extension in favour of least developed countries is to allow additional access to generic medicines. Post the transition period, efforts are needed to protect what has been achieved. This is necessary because of the stifled research and development for new drugs on neglected tropical diseases and the current trend of the abuse of intellectual property enforcement measures provided for in the Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPs). Finding the right balance between health, trade and Intellectual Property policies to sustain innovation and ensure widespread access to life-saving technologies is one of the primary public policy challenges of our time.
dc.format.mediumapplication/pdf
dc.language.isoeng
dc.publisherCODESRIA
dc.relation.ispartofhttps://www.ajol.info/index.php/ad/article/view/163623/153101
dc.rightsCopyright for articles published in this journal is retained by the journal.
dc.sourceAfrica Development; Vol 42, No 1 (2017); 101-120
dc.titleAccess to Drugs at Risk: Securing Access to Medicines for Least Developed Countries
dc.typeinfo:eu-repo/semantics/article
ge.collectioncode0850-3907
ge.dataimportlabelOAI metadata object
ge.identifier.legacyglobethics:12244117
ge.identifier.permalinkhttps://www.globethics.net/gel/12244117
ge.lastmodificationdate2017-12-15 00:19
ge.lastmodificationuseradmin@pointsoftware.ch (import)
ge.submissions0
ge.oai.exportid148924
ge.oai.repositoryid224
ge.oai.setnameArticles
ge.oai.setspecad:ART
ge.oai.streamid2
ge.setnameGlobeEthicsLib
ge.setspecglobeethicslib
ge.linkhttps://www.ajol.info/index.php/ad/article/view/163623


This item appears in the following Collection(s)

Show simple item record